National Jewish Health researchers have shown that a low-cost pulmonary surfactant inhibits binding of respiratory syncytial virus to lung epithelial surfaces. Although issues related to both prophylactic and treatment applications need to be worked out, the researchers believe the path to human trials could be relatively short.